Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp

The Follicular Lymphoma market growth is driven by factors like increase in the prevalence of Follicular Lymphoma, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Follicular Lymphoma market report [https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Follicular Lymphoma market size, share, Follicular Lymphoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Follicular Lymphoma market size growth forward.

Some of the key highlights from the Follicular Lymphoma Market Insights Report:

*
Several key pharmaceutical companies, including Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, and others, are developing novel products to improve the Follicular Lymphoma treatment outlook.

*
In August 2024, the company plans to submit a supplemental Biologics License Application for tafasitamab to treat FL patients who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy, based on the positive Phase III results.

*
In June 2024, a consortium led by Eugene Private Equity and Korea Development Bank Private Equity announced they would acquire 80% of the South Korean vaccine maker Boryung Biopharma Co. for 320 billion won (USD 231 million).

*
In February 2024, Incyte revealed that it had entered into an asset purchase agreement with MorphoSys AG, granting Incyte exclusive global rights to tafasitamab. As a result, Incyte will take on revenue and costs for all U.S. commercialization and clinical development, while MorphoSys will no longer receive future milestone, profit split, or royalty payments.

*
As per DelveInsight analysis, the Follicular Lymphoma market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Follicular Lymphoma Market Landscape [https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Follicular Lymphoma Overview

Follicular lymphoma (FL) is a slow-growing B-cell lymphoproliferative disorder, mainly characterized by swollen lymph nodes, bone marrow involvement, and spleen enlargement, though extranodal involvement is rare. Common symptoms include fatigue, shortness of breath, night sweats, and weight loss, but many patients show no symptoms at the time of diagnosis. It is generally considered a chronic disease, as it is not typically curable, but patients often live many years with it.

The WHO grading system for FL classifies it into grades 1, 2, or 3 based on the number of centroblasts. Grade 1 (small cleaved cells) has 0-5 centroblasts/HPF, grade 2 (mixed) has 6-15 centroblasts/HPF, and grade 3 (large cell) has more than 15 centroblasts/HPF. Differentiating between grades 1/2 and grade 3 is clinically significant.

Diagnosis is made through histological examination of a lymph node or affected tissue biopsy. Immunohistochemical staining for CD19, CD20, CD10, monoclonal immunoglobulin, and bcl-2 protein is positive in nearly all cases, with a majority showing a t(14;18) translocation involving the IgH/bcl-2 genes.

Treatment depends on disease stage, with options including radiation, immunochemotherapy (Rituximab plus chemotherapy), and combinations like CHOP, CVP, or Bendamustine. Recent advances show that CAR T-cell therapy (like Yescarta) holds promise for treating indolent FL, with other CAR T options, Kymirah and Breyanzi, under investigation for relapsed/refractory cases. New bispecific antibodies, such as Mosunetuzumab and Odronextamab, are also showing promise, offering lower toxicity and easier administration.

Do you know the treatment paradigms for different countries? Download our Follicular Lymphoma Market Sample Report [https://www.delveinsight.com/sample-request/follicular-lymphoma-market-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Follicular Lymphoma Epidemiology Segmentation

DelveInsight's Follicular Lymphoma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Follicular Lymphoma historical patient pools and forecasted Follicular Lymphoma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Follicular Lymphoma Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:

*
Follicular Lymphoma Prevalence

*
Age-Specific Follicular Lymphoma Prevalence

*
Gender-Specific Follicular Lymphoma Prevalence

*
Diagnosed and Treatable Cases of Follicular Lymphoma

Visit for more @ Follicular Lymphoma Epidemiological Insights [https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Follicular Lymphoma Market Outlook

Tazemetostat is the first oral EZH2 inhibitor approved for relapsed or refractory follicular lymphoma (FL) after two or more lines of treatment, or for EZH2 wild-type or unknown cases in patients with no satisfactory alternatives. EZH2, a histone methyltransferase prevalent in the germinal center where FL originates, is mutated in about 20% of FL cases. Tazemetostat inhibits both the mutated and wild-type forms of EZH2, with better response rates observed in patients with the mutated form.

In May 2019, the combination of lenalidomide (Revlimid) and rituximab (Rituxan, or R2) was approved for adult patients with previously treated grade 1-3A FL. This targeted therapy offers a new option, but with the upcoming patent expiry, generic lenalidomide is expected to enter the market soon.

Chimeric antigen receptor (CAR) T-cell therapy is another promising treatment. Gilead's Kite recently received FDA accelerated approval for Yescarta, the first CAR-T cell therapy approved for indolent FL.

PI3K inhibitors, such as idelalisib, copanlisib, and duvelisib, are also significant treatments for relapsed or refractory FL, targeting the p110 isoform of PI3K involved in B-cell development and signaling. Idelalisib, approved in 2014, is specifically indicated for relapsed FL but carries a boxed warning for severe side effects, including liver toxicity, diarrhea, colitis, pneumonitis, and intestinal perforation.

Follicular Lymphoma Emerging Drugs

*
Monjuvi/Tafasitamab (Incyte Corporation/MorphoSys)

*
Breyanzi/JCAR017 (Bristol Myers)

Follicular Lymphoma Key Companies

*
Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corporation, Bristol Myers Squibb, ADC Therapeutics, MorphoSys, Nordic Nanovector, AbbVie, Regeneron Pharmaceuticals, Janssen Research & Development, Novartis, MEI Pharma, and BeiGene, and others

For more information, visit Follicular Lymphoma Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/follicular-lymphoma-market-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Follicular Lymphoma Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Follicular Lymphoma, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Follicular Lymphoma epidemiology in the 7MM

*
Follicular Lymphoma marketed and emerging therapies

*
Follicular Lymphoma companies

*
Follicular Lymphoma market drivers and barriers

Table of Contents:

1 Follicular Lymphoma Market Key Comprehensive Insights

2 Follicular Lymphoma Market Report Introduction

3 Competitive Intelligence Analysis for Follicular Lymphoma

4 Follicular Lymphoma Market Analysis Overview at a Glance

5 Executive Summary of Follicular Lymphoma

6 Follicular Lymphoma Epidemiology and Market Methodology

7 Follicular Lymphoma Epidemiology and Patient Population

8 Follicular Lymphoma Patient Journey

9 Follicular Lymphoma Treatment Algorithm, Follicular Lymphoma Current Treatment, and Medical Practices

10 Key Endpoints in Follicular Lymphoma Clinical Trials

11 Follicular Lymphoma Marketed Therapies

12 Follicular Lymphoma Emerging Therapies

13 Follicular Lymphoma: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Follicular Lymphoma

16 Follicular Lymphoma Market Key Opinion Leaders Reviews

18 Follicular Lymphoma Market Drivers

19 Follicular Lymphoma Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Follicular Lymphoma Epidemiology 2034

DelveInsight's "Follicular Lymphoma - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Follicular Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Follicular Lymphoma Pipeline 2024

"Follicular Lymphoma Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Follicular Lymphoma market. A detailed picture of the Follicular Lymphoma pipeline landscape is provided, which includes the disease overview and Follicular Lymphoma treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=follicular-lymphoma-market-expected-to-rise-2034-epizymeeisai-bayer-healthcare-pharmaceuticals-verastem-oncology-gilead-sciences-tg-therapeutics-bristolmyerssquibb-roche-incyte-corp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.